✅ Product Benefits & Highlights

• Targeted therapy for PBC: Indicated for adult patients with primary biliary cholangitis—especially those who have inadequate response to UDCA or can’t tolerate it.

• FXR receptor agonist: Obeticholic acid (Livacol) activates the Farnesoid X Receptor to reduce hepatic bile acid load, inflammation, and fibrosis.

• Standard dosing regimen: Start with 5 mg once daily; if response is inadequate after ~3 months, dose may be raised to 10 mg once daily.

• Local availability at a competitive price: Widely available in Bangladesh for approximately ৳30 per tablet or ৳300 per 10‑tablet strip.

⚠️ Safety, Side Effects & Precautions

• Liver toxicity risk: Hepatic decompensation or failure, sometimes fatal, has been reported in patients with cirrhosis—even at recommended dosing. Regular monitoring of liver function is essential.

• Common side effects:

  • Intense or widespread pruritus, reported in up to 23% of patients receiving 10 mg.

  • Fatigue, abdominal discomfort, rash, arthralgia, oropharyngeal pain, dizziness, constipation, and eczema.

• Laboratory concerns: Dose-dependent reduction in HDL-C levels—up to 20% decline at higher dose levels. Lipid profiles should be monitored during therapy.

• Drug interactions & cautions:

  • Bile acid–binding resins may reduce absorption—space doses at least 4 hours apart.

  • Co‑administration with warfarin may lower INR—monitor anticoagulation.

  • May increase levels of CYP1A2 substrate drugs (e.g., theophylline, tizanidine)—monitor closely.

🧠 Why This SEO Strategy Works

• Targets both brand ("Livacol 5 mg") and generic ("Obeticholic Acid") search terminology.

• Captures condition-specific terms frequently searched in Bangladesh: “PBC”, “cholestatic liver disease”, and “bile acid regulator.”

• Includes local context by emphasizing price, availability, and Bangladeshi manufacturing.

• Balances therapeutic benefits with clear safety-related keywords often researched by patients and healthcare providers.